Trend
DailyDowntrend (confirmed)
4 hourAscending Triangle
1 hourLeaning Bearish
15 minStrong Bearish
5 minLeaning Bullish
Daily trend turns up above $16.12
Key levels
Resistance$12.14
Resistance$11.34
Support$10.31
Support$9.62
Latest news & SEC filings
AnalystRBC Capital keeps Outperform rating on Design Therapeutics, cuts target to $19
EarningsDesign Therapeutics Posts Q3 2026 Financials
DealDesign Therapeutics files $300M mixed shelf offering prospectus
All DSGN news →Design Therapeutics is a biopharmaceutical firm in the clinical stage that develops small-molecule GeneTAC treatments. These drugs are intended to fix faulty gene activity underlying disorders tied to repeated DNA sequences. Its programs address Friedreich ataxia, an eye condition called FECD, DM1, and HD. The company operates in the United States.
Based on the company's 10-K filed Mar 9, 2026.
Nasdaq · Healthcare
SEPT Low Target
$21.00
SEPT Mid Target
$23.50
SEPT High Target
$26.00
Analyst Consensus
$23.50
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for DSGN.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$19.70
12
Moat Score
NONE
1/9
Piotroski Score
23.6
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-38.64%
FCF Growth YoY
-25.6%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for DSGN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:25 | $10.58 | 1,100 | $$12K | SELL |
| 21:00:24 | $10.58 | 1,115 | $$12K | SELL |
| 21:00:24 | $10.58 | 1,433 | $$15K | SELL |
| 20:04:46 | $10.69 | 5,198 | $$56K | SELL |
| 20:04:46 | $10.73 | 1,200 | $$13K | BUY |
5 dark pool trades shown · $$107K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Design Therapeutics, Inc. (DSGN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (0 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Design Therapeutics, Inc. (DSGN) is at $10.58, down 1.76% (-$0.19) at the Nov 12, 2026 close.
Latest DSGN news — Nov 5, 2026: RBC Capital keeps Outperform rating on Design Therapeutics, cuts target to $19 · Nov 5, 2026: Design Therapeutics Posts Q3 2026 Financials
The average analyst price target for DSGN is $23.50, ranging from $21 to $26, based on 2 analysts. Latest: Wells Fargo initiates on Oct 2, 2026.
Analyst ratings for DSGN: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
DSGN last reported on Aug 3, 2026: EPS -$0.32 vs -$0.34 expected — a beat of 7.1%.
DSGN does not currently pay a dividend.
Support: $10.31, $9.62, $8.82. Resistance: $11.34, $12.14, $12.82.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
Nov 5, 2026: RBC Capital keeps Outperform rating on Design Therapeutics, cuts target to $19 · Nov 5, 2026: Design Therapeutics Posts Q3 2026 Financials · Nov 4, 2026: Design Therapeutics files $300M mixed shelf offering prospectus